<DOC>
	<DOCNO>NCT00468689</DOCNO>
	<brief_summary>This study evaluate safety , tolerability exposure SB-751689 administer alone supratherapeutic dos SB-751689 co administer ketoconazole , PGP/CYP3A4 inhibitor increase exposure SB-751689 . Data study enable plan conduct QTc study SB-751689 .</brief_summary>
	<brief_title>Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy adult age 1860yrs , BMI 1931kg/m2 . Females must nonchildbearing potential . Subjects must able give consent comply restriction study . Clinically relevant abnormality history , physical , 12lead ECG , Holter monitoring , clinical laboratory examination . Positive urine drug screen . Positive urine test alcohol . Contine level indicative smoking . Positive HIV Hep B and/or C assay . History smoking last year &gt; 10 pack/year history smoke overall . History regular alcohol consumption ( 7 units/week woman 14 units/week men ) within 6 month study . History drug abuse within 6 month study . Participation another drug trial within 30 day first dose . Exposure 4 new chemical entity within 12 month first dose . Use prescription nonprescription drug include dietary supplement , herbal St. John 's wort within 14 day first dose . Consumption red wine , grapefruit , grapefruit juice grapefruit product within 14 day first dose . Donation blood excess 500 mL within 56 day dose . Evidence renal , hepatic biliary impairment . History serious gastrointestinal disease history gastrointestinal surgical procedure might affect absorption study drug . History sensitivity study medication . History clinically significant cardiovascular disease . History pernicious anemia , pancreatitis , osteosarcoma kidney stone . Medical condition might alter bone metabolism . Liver function test ULN screen PTH , glucose , CPK outside reference range screening . Males unwilling refrain father child study 14 day follow last dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>SB-751689 ,</keyword>
	<keyword>Calcium-sensing receptor antagonist ( CaR ) ,</keyword>
	<keyword>Osteoporosis ,</keyword>
	<keyword>Parathyroid hormone ( PTH ) ,</keyword>
	<keyword>Oral dose</keyword>
</DOC>